Rectal neuroendocrine tumors in a Latin American population: Insights from a Peruvian national cancer institute

Table 6 Overall survival estimates according to clinical and pathological characteristics

Variables	n (events)	1-year	3-year	5-year	P value
All patients	52 (15)	92.9%	73.4%	60.6%	N/A
Age in years					0.86
< 65	44 (13)	93.9%	71.1%	61.6%
≥ 65	8 (2)	87.5%	87.5%	43.8%
Sex					0.34
Female	34 (9)	100%	71.2%	64.7%
Male	18 (6)	78.0%	78.0%	52.0%
Grade					0.00032
G1	27 (3)	100%	92.9%	92.9%
G2	25 (12)	87.1%	57.0%	32.6%
Ki-67 (%)					0.00032
< 3	27 (3)	100%	92.9%	92.9%
3-20	25 (12)	87.1%	57.0%	32.6%
Tumor size (cm)					0.048
≤ 1	24 (3)	100%	91.7%	91.7%
> 1	28 (12)	87.6%	62.8%	43.9%
Tumor size (cm)					0.0056
≤ 2	31 (4)	95.8%	89.4%	89.4%
> 2	21 (11)	89.9%	59.1%	37.0%
Classification N					0.0063
N0	31 (4)	100%	94.1%	84.7%
N1	21 (11)	83.9%	51.9%	37.1%
Disease stage					0.00049
Advanced	23 (13)	86.5%	58.8%	39.2%
Localized	29 (2)	100%	92.9%	92.9%
First-line chemotherapy					0.086
No	32 (5)	92.0%	76.7%	76.7%
Yes	20 (10)	94.4%	69.6%	46.4%

G: Grade; N: Node; N/A: Not applicable.